Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Liquid-based cytology can identify higher lymphocyte counts in endometrial cancer patients with specific mutations (POLEmut, MMR-d) and high tumor mutation burden (TMB-high). This finding aids in predicting immunotherapy response for these patient groups.
Area Of Science
- Gynecologic Oncology
- Cancer Genomics
- Immunotherapy Biomarkers
Background
- Patients with POLE mutations (POLEmut), MMR-deficient (MMR-d) subtypes, and high tumor mutation burden (TMB-high) may benefit from immunotherapy.
- Cytological morphology characteristics in these immunotherapy-responsive endometrial cancer populations are not well understood.
Purpose Of The Study
- To investigate the cytological morphology, specifically lymphocyte and neutrophil counts, in relation to The Cancer Genome Atlas (TCGA) molecular subtypes and tumor mutation burden (TMB) in endometrial cancer.
- To determine if cytological features can predict immunotherapy responsiveness.
Main Methods
- Next-generation sequencing was used to analyze DNA from formalin-fixed paraffin-embedded tissues for mutations, TMB, and microsatellite instability.
- Endometrial cancer liquid-based cytology samples were analyzed for cytological backgrounds, neutrophil counts, and lymphocyte counts.
- Samples were classified into four TCGA groups and stratified by TMB status (TMB-high vs. TMB-low).
Main Results
- No significant differences in cytological background patterns were observed across TCGA groups or TMB status.
- POLEmut and MMR-d groups showed significantly higher lymphocyte counts compared to the no specific molecular profile (NSMP) group.
- Lymphocyte counts were significantly higher in TMB-high compared to TMB-low groups.
- Lymphocyte count demonstrated good diagnostic accuracy (AUC=0.70) for predicting POLEmut plus MMR-d status.
Conclusions
- Lymphocyte count in liquid-based cytology is a potential predictive biomarker for identifying endometrial cancer patients with POLEmut plus MMR-d and TMB-high.
- These findings suggest that lymphocyte count can help select patients who may benefit from immunotherapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
